The first relapse in multiple myeloma: how to pick the next best thing

被引:1
作者
Devarakonda, Srinivas [1 ]
Sharma, Nidhi [1 ]
Efebera, Yvonne [2 ,3 ]
机构
[1] Ohio State Univ, Dept Internal Med, Div Hematol, Columbus, OH USA
[2] OhioHealth, Div Blood & Marrow Transplantat, Columbus, OH USA
[3] OhioHealth, 500 Thomas Ln, Columbus, OH 43214 USA
关键词
STEM-CELL TRANSPLANTATION; OPEN-LABEL; LENALIDOMIDE MAINTENANCE; DOUBLE-BLIND; DEXAMETHASONE; CARFILZOMIB; SURVIVAL; DARATUMUMAB; BORTEZOMIB; IXAZOMIB;
D O I
10.1182/hematology.2022000356
中图分类号
G40 [教育学];
学科分类号
040101 ; 120403 ;
摘要
The choice of treat ment for patients with mul ti ple mye loma (MM) at fi rst relapse / pro gres sion is based on many fac tors: (1) treat ment - related fac tors, which include the reg i men used dur ing first induc tion, the qual ity and dura tion of first response achieved, toxicities from the first treat ment, whether the patient under went autol o gous stem cell trans plant, and whether the patient was on main te nance at the time of relapse / pro gres sion; (2) dis ease - related fac tors, includ ing dis ease pre sen ta tion and pace of pro gres sion; and (3) patient - related fac tors, includ ing func tional age and per for mance sta tus. The learn ing objec tives are to pres ent the treat ment options for patients with MM upon their fi rst relapse and to learn about various strategies for selecting an optimal treatment regimen.
引用
收藏
页码:560 / 568
页数:9
相关论文
共 49 条
  • [31] Moreau P, 2021, LANCET ONCOL, V22, pE105, DOI 10.1016/S1470-2045(20)30756-7
  • [32] Once-weekly (70 mg/m2) vs twice-weekly (56 mg/m2) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, ARROW, and CHAMPION-1 trials
    Moreau, Philippe
    Stewart, Keith A.
    Dimopoulos, Meletios
    Siegel, David
    Facon, Thierry
    Berenson, James
    Raje, Noopur
    Berdeja, Jesus G.
    Orlowski, Robert Z.
    Yang, Hui
    Ma, Haijun
    Klippel, Zandra
    Zahlten-Kumeli, Anita
    Mezzi, Khalid
    Iskander, Karim
    Mateos, Maria-Victoria
    [J]. CANCER MEDICINE, 2020, 9 (09): : 2989 - 2996
  • [33] Guidance for Use and dosing of Selinexor in Multiple Myeloma in 2021: Consensus From International Myeloma Foundation Expert Roundtable
    Nooka, A. K.
    Costa, L. J.
    Gasparetto, C. J.
    Richardson, P. G.
    Siegel, D. S.
    Chari, A.
    Lentzsch, S.
    Jagannath, S.
    Mikhael, J.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (07) : E526 - E531
  • [34] International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation
    Palumbo, A.
    Sezer, O.
    Kyle, R.
    Miguel, J. S.
    Orlowski, R. Z.
    Moreau, P.
    Niesvizky, R.
    Morgan, G.
    Comenzo, R.
    Sonneveld, P.
    Kumar, S.
    Hajek, R.
    Giralt, S.
    Bringhen, S.
    Anderson, K. C.
    Richardson, P. G.
    Cavo, M.
    Davies, F.
    Blade, J.
    Einsele, H.
    Dimopoulos, M. A.
    Spencer, A.
    Dispenzieri, A.
    Reiman, T.
    Shimizu, K.
    Lee, J. H.
    Attal, M.
    Boccadoro, M.
    Mateos, M.
    Chen, W.
    Ludwig, H.
    Joshua, D.
    Chim, J.
    Hungria, V.
    Turesson, I.
    Durie, B. G. M.
    Lonial, S.
    [J]. LEUKEMIA, 2009, 23 (10) : 1716 - 1730
  • [35] Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
    Palumbo, Antonio
    Chanan-Khan, Asher
    Weisel, Katja
    Nooka, Ajay K.
    Masszi, Tamas
    Beksac, Meral
    Spicka, Ivan
    Hungria, Vania
    Munder, Markus
    Mateos, Maria V.
    Mark, Tomer M.
    Qi, Ming
    Schecter, Jordan
    Amin, Himal
    Qin, Xiang
    Deraedt, William
    Ahmadi, Tahamtan
    Spencer, Andrew
    Sonneveld, Pieter
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (08) : 754 - 766
  • [36] Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report
    Palumbo, Antonio
    Bringhen, Sara
    Mateos, Maria-Victoria
    Larocca, Alessandra
    Facon, Thierry
    Kumar, Shaji K.
    Offidani, Massimo
    McCarthy, Philip
    Evangelista, Andrea
    Lonial, Sagar
    Zweegman, Sonja
    Musto, Pellegrino
    Terpos, Evangelos
    Belch, Andrew
    Hajek, Roman
    Ludwig, Heinz
    Stewart, A. Keith
    Moreau, Philippe
    Anderson, Kenneth
    Einsele, Hermann
    Durie, Brian G. M.
    Dimopoulos, Meletios A.
    Landgren, Ola
    San Miguel, Jesus F.
    Richardson, Paul
    Sonneveld, Pieter
    Rajkumar, S. Vincent
    [J]. BLOOD, 2015, 125 (13) : 2068 - 2074
  • [37] Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Followup Analysis of the IFM 2009 Trial
    Perrot, Aurore
    Lauwers-Cances, Valerie
    Cazaubiel, Titouan
    Facon, Thierry
    Caillot, Denis
    Clement-Filliatre, Lauriane
    Macro, Margaret
    Decaux, Olivier
    Belhadj, Karim
    Mohty, Mohamad
    Karlin, Lionel
    Eisenmann, Jean Claude
    Tiab, Mourad
    Orsini, Frederique
    Touzeau, Cyrille
    Leleu, Xavier
    Avet-Loiseau, Herve
    Munshi, Nikhil C.
    Anderson, Kenneth
    Richardson, Paul G.
    Moreau, Philippe
    Attal, Michel
    [J]. BLOOD, 2020, 136
  • [38] Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma
    Richardson, Paul G.
    Jacobus, Susanna J.
    Weller, Edie A.
    Hassoun, Hani
    Lonial, Sagar
    Raje, Noopur S.
    Medvedova, Eva
    McCarthy, Philip L.
    Libby, Edward N.
    Voorhees, Peter M.
    Orlowski, Robert Z.
    Anderson, Larry D.
    Zonder, Jeffrey A.
    Milner, Carter P.
    Gasparetto, Cristina
    Agha, Mounzer E.
    Khan, Abdullah M.
    Hurd, David D.
    Gowin, Krisstina
    Kamble, Rammurti T.
    Jagannath, Sundar
    Nathwani, Nitya
    Alsina, Melissa
    Cornell, R. Frank
    Hashmi, Hamza
    Campagnaro, Erica L.
    Andreescu, Astrid C.
    Gentile, Teresa
    Liedtke, Michaela
    Godby, Kelly N.
    Cohen, Adam D.
    Openshaw, Thomas H.
    Pasquini, Marcelo C.
    Giralt, Sergio A.
    Kaufman, Jonathan L.
    Yee, Andrew J.
    Scott, Emma
    Torka, Pallawi
    Foley, Amy
    Fulciniti, Mariateresa
    Hebert, Kyle
    Samur, Mehmet K.
    Masone, Kelly
    Maglio, Michelle E.
    Zeytoonjian, Andrea A.
    Nadeem, Omar
    Schlossman, Robert L.
    Laubach, Jacob P.
    Paba-Prada, Claudia
    Ghobrial, Irene M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (02) : 132 - 147
  • [39] Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
    Richardson, Paul G.
    Kumar, Shaji K.
    Masszi, Tamas
    Grzasko, Norbert
    Bahlis, Nizar J.
    Hansson, Markus
    Pour, Ludek
    Sandhu, Irwindeep
    Ganly, Peter
    Baker, Bartrum W.
    Jackson, Sharon R.
    Stoppa, Anne-Marie
    Gimsing, Peter
    Garderet, Laurent
    Touzeau, Cyrille
    Buadi, Francis K.
    Laubach, Jacob P.
    Cavo, Michele
    Darif, Mohamed
    Labotka, Richard
    Berg, Deborah
    Moreau, Philippe
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (22) : 2430 - +
  • [40] Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
    Richardson, Paul G.
    Oriol, Albert
    Beksac, Meral
    Liberati, Anna Marina
    Galli, Monica
    Schjesvold, Fredrik
    Lindsay, Jindriska
    Weisel, Katja
    White, Darrell
    Facon, Thierry
    Miguel, Jesus Son
    Sunami, Kazutaka
    O'Gorman, Peter
    Sonneveld, Pieter
    Robak, Pawel
    Semochkin, Sergey
    Schey, Steve
    Yu, Xin
    Doerr, Thomas
    Bensmaine, Amine
    Biyukov, Tsvetan
    Peluso, Teresa
    Zaki, Mohamed
    Anderson, Kenneth
    Dimopoulos, Meletios
    [J]. LANCET ONCOLOGY, 2019, 20 (06) : 781 - 794